Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 7/20 | 0.80 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.80 |
| ▸ | HIF1A | Q16665 | 6/20 | 0.80 |
| ▸ | SHBG | P04278 | 4/20 | 0.80 |
| ▸ | SERPINA6 | P08185 | 4/20 | 0.80 |
| ▸ | LMNA | P02545 | 4/20 | 0.80 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.80 |
| ▸ | MAPT | P10636 | 3/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.80 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.80 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.80 |
| ▸ | BLM | P54132 | 1/20 | 0.80 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.80 |
| ▸ | TSHR | P16473 | 1/20 | 0.80 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.80 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.80 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.80 |
| ▸ | THPO | P40225 | 1/20 | 0.80 |
| ▸ | MTOR | P42345 | 1/20 | 0.80 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19327108 | 1.00 | NR3C2 (0.80) | NR3C2SMN1; SMN2HIF1ASHBGSERPINA6 | |
| SCHEMBL3232371 | 1.00 | NR3C2 (0.80) | NR3C2SMN1; SMN2HIF1ASHBGSERPINA6 | |
| SCHEMBL15763286 | 1.00 | NR3C2 (0.80) | NR3C2SMN1; SMN2HIF1ASHBGSERPINA6 | |
| SCHEMBL21231249 | 0.91 | HIF1A (0.76) | NR3C2SMN1; SMN2HIF1ASHBGSERPINA6 | |
| SCHEMBL11211928 | 0.90 | NR3C2 (0.73) | NR3C2SMN1; SMN2HIF1ASHBGSERPINA6 | |
| SCHEMBL11211930 | 0.90 | NR3C2 (0.73) | NR3C2SMN1; SMN2HIF1ASHBGSERPINA6 | |
| Epicorticosterone SCHEMBL4380327 | 0.89 | SMN1; SMN2 (1.00) | NR3C2SMN1; SMN2HIF1ASHBGSERPINA6 | |
| Corticosterone SCHEMBL22612 | 0.89 | SMN1; SMN2 (1.00) | NR3C2SMN1; SMN2HIF1ASHBGSERPINA6 | |
| Epicorticosterone SCHEMBL21168995 | 0.89 | SMN1; SMN2 (1.00) | NR3C2SMN1; SMN2HIF1ASHBGSERPINA6 | |
| Epicorticosterone SCHEMBL20058459 | 0.89 | SMN1; SMN2 (1.00) | NR3C2SMN1; SMN2HIF1ASHBGSERPINA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 804 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12280021-B2 | Affinity medicant conjugate | AF CHEMICALS, LLC (US) | 2025-04-22 | — | — | US | claimed |
| US-20250041208-A1 | NEW INJECTABLE COMBINATION FORMULATION | NANEXA AB (SE) | 2025-02-06 | — | — | US | claimed |
| CN-119125354-A | Method and kit for measuring various steroid hormones in body fluid by liquid chromatography-mass spectrometry technology | 浙江博圣生物技术股份有限公司 | 2024-12-13 | — | — | CN | claimed |
| CN-119125357-A | Kit for simultaneously detecting multiple steroid hormones in dried blood spots based on liquid chromatography-mass spectrometry and application of kit | 浙江博圣生物技术股份有限公司 | 2024-12-13 | — | — | CN | claimed |
| CN-118647367-A | Novel injectable combination formulations | 南爱克萨股份公司 | 2024-09-13 | — | — | CN | claimed |
| CN-114965786-B | Method for detecting various intermediate metabolites of ester cholesterol in dried blood spots | 重庆医科大学附属儿童医院 | 2023-11-03 | — | — | CN | claimed |
| CN-116660543-A | Diagnostic and prognostic markers for nonalcoholic fatty liver disease and uses thereof | 中国人民解放军陆军军医大学第一附属医院 | 2023-08-29 | — | — | CN | claimed |
| CN-114895043-B | Primary aldosteronism screening kit and definite diagnosis and typing diagnosis system | 杭州凯莱谱精准医疗检测技术有限公司 | 2022-12-13 | — | — | CN | claimed |
| EP-4076470-A1 | TREATMENT OF, AND DIFFERENTIAL DIAGNOSIS BETWEEN, ACTH-DEPENDENT CUSHING'S SYNDROME AND ACTH-INDEPENDENT CUSHING'S SYNDROME | Corcept Therapeutics Incorporated (US) | 2022-10-26 | — | — | EP | claimed |
| CN-115236246-A | Method for extracting multiple steroid hormones from organism fluid sample | 北京金域医学检验实验室有限公司 | 2022-10-25 | — | — | CN | claimed |
| EP-2070550-A1 | Use of combinations comprising a corticosteroid and a pyrimidopyrimidine in the treatment of inflammatory diseases | Combinatorx, Incorporated (US) | 2009-06-17 | — | — | EP | claimed |
| US-20080261304-A1 | METHODS AND COMPOSITIONS FOR ENHANCING DELIVERY OF DOUBLE-STRANDED RNA OR A DOUBLE-STRANDED HYBRID NUCLEIC ACID TO REGULATE GENE EXPRESSION IN MAMMALIAN CELLS | NASTECH PHARMACEUTICAL COMPANY INC. (US) | 2008-10-23 | — | — | US | claimed |
| EP-1962856-A2 | MEDICAMENT BASED ON A MONOESTER OF STEROIDS WITH LONG CHAIN FATTY ACIDS | Petroni, Anna (IT) | 2008-09-03 | — | — | EP | claimed |
| WO-2007068434-A2 | MEDICAMENT BASED ON A MONOESTER OF STEROIDS WITH LONG CHAIN FATTY ACIDS | PETRONI ANNA (IT) | 2007-06-21 | — | — | WO | claimed |
| EP-1773998-A2 | METHODS AND COMPOSITIONS FOR ENHANCING DELIVERY OF DOUBLE-STRANDED RNA OR A DOUBLE-STRANDED HYBRID NUCLEIC ACID TO REGULATE GENE EXPRESSION IN MAMMALIAN CELLS | Nastech Pharmaceutical Company Inc. (US) | 2007-04-18 | — | — | EP | claimed |
| US-20070010502-A1 | Methods and reagents for the treatment of immunoinflammatory disorders | COMBINATORX INC. (US) | 2007-01-11 | — | — | US | claimed |
| WO-2006019430-A2 | METHODS AND COMPOSITIONS FOR ENHANCING DELIVERY OF DOUBLE-STRANDED RNA OR A DOUBLE-STRANDED HYBRID NUCLEIC ACID TO REGULATE GENE EXPRESSION IN MAMMALIAN CELLS | NASTECH PHARMACEUTICAL COMPANY INC. (US) | 2006-02-23 | — | — | WO | claimed |
| US-20060014289-A1 | Methods and compositions for enhancing delivery of double-stranded RNA or a double-stranded hybrid nucleic acid to regulate gene expression in mammalian cells | NASTECH PHARMACEUTICAL COMPANY INC. (US) | 2006-01-19 | — | — | US | claimed |
| EP-0033341-A1 | CYTOTOXIC NUCLEOSIDE-CORTICOSTEROID PHOSPHODIESTERS | Research Corporation (US) | 1981-08-12 | — | — | EP | claimed |
| WO-1981000410-A1 | CYTOTOXIC NUCLEOSIDE-CORTICOSTEROID PHOSPHODIESTERS | RESEARCH CORP (US) | 1981-02-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12280021-B2 | Affinity medicant conjugate | FCER2, HDGF, FCGR2A | NR3C2 606/4885SMN1; SMN2 3267/4885HIF1A 2191/4885 |
| US-20080261304-A1 | METHODS AND COMPOSITIONS FOR ENHANCING DELIVERY OF DOUBLE-STRANDED RNA OR A DOUBLE-STRANDED HYBRID NUCLEIC ACID TO REGULATE GENE EXPRESSION IN MAMMALIAN CELLS | SNRPE, LDLR, SNRPA | NR3C2 2035/4885SMN1; SMN2 515/4885HIF1A 789/4885 |
| US-20070010502-A1 | Methods and reagents for the treatment of immunoinflammatory disorders | IL5, TPMT, TSLP | NR3C2 796/4885SMN1; SMN2 1541/4885HIF1A 1602/4885 |
| US-20060014289-A1 | Methods and compositions for enhancing delivery of double-stranded RNA or a double-stranded hybrid nucleic acid to regulate gene expression in mammalian cells | SNRPE, SREBF2, SREBF1 | NR3C2 3756/4885SMN1; SMN2 1279/4885HIF1A 1123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.